Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NITROGLYCERIN CONTROLLED-RELEASE ORAL CAPS/TABS ARE "EFFECTIVE" FOR ANGINA PREVENTION: LABELING STRENGTHENS DRUG TOLERANCE PRECAUTIONS; BIO-STUDIES NEEDED

Executive Summary

Nitroglycerin controlled-release oral caps and tabs must carry strengthened label precautions concerning drug tolerance as a condition for continued marketing as DESI effective drugs, FDA stipulated in a Sept. 7 Federal Register notice. The labeling revisions are included in an FDA notice announcing the products' upgrading to effective under the DESI review. The controlled-release oral form is the third dosage form of nitroglycerin to clear the DESI review program. Both I.V. and sublingual forms of nitroglycerin have also been approved, but three other dosage formulations remain subject to final FDA decisions on efficacy -- ointment, controlled-release buccal tabs and transdermal patches. FDA based its determination that the controlled-release oral formulations are effective in the prevention of angina pectoris on data submitted by two firms, Marion and Wharton Labs, a division of U.S. Ethicals. FDA's "general outline" for revised labeling for the products extends the tolerance precautions contained in current labeling. The current labeling states: "Tolerance to this drug and cross-tolerance to other nitrates and nitrites may occur." The revised labeling for controlled-release nitroglycerin oral caps and tabs adds that "tolerance to the vascular and antianginal effects of nitrates has been demonstrated in clinical trials, experience through occupational exposure, and in isolated tissue experiments in the laboratory." Although it notes that "the relative importance of these observations to the routine, clinical use of nitroglycerin are not known," the labeling advises physicians against abrupt withdrawal of nitroglycerin therapy."It seems prudent to gradually withdraw patients from nitroglycerin when the therapy is being terminated, rather than stopping the drug abruptly." The agency also said that it will require bioavailability data for the products. Noting that studies are currently underway to establish "absolute and relative bioavailability for oral nitroglycerin," FDA said mfrs. "will be required to match these standards by performing bioavailability/bioequivalence studies." According to the labeling, clinical trials involving angina patients found that "sustained therapy with some nitrate preparations resulted in significantly less and shorter duration of improvement in exercise time on stress testing than did acute therapy." The labeling notes, however, that a study of 18 angina patients showed "significantly better" treadmill performances among patients receiving "repetitive doses of oral nitroglycerin" than those on placebo "after two weeks of therapy." In addition, the labeling cites the occurrence of tolerance and physicial dependence to nitroglycerin by industrial workers continuously exposed to nitroglycerin. "Physical dependence also occurs since chest pain, acute myocardial infarction and even sudden death have occurred during temporary withdrawal of nitroglycerin from the workers," it says. Chart omitted.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS007148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel